Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZ sharemarket starts week up 0.6%
Markets Market Close

NZ sharemarket starts week up 0.6%

The S&P/NZX 50 Index closed at 13,449.85, up 80.45 points or 0.6%.

Kiwi Property Group's interim profit lower as write-downs bite
Economy

Kiwi Property Group's interim profit lower as write-downs bite

The property company reiterates its full-year dividend views.

Gentrack in the hunt for 10 new customers
Markets

Gentrack in the hunt for 10 new customers

Shares climb more than 14% on hopes of at least three or four new customers.  

Another solar farm gets the nod from Genesis
Markets

Another solar farm gets the nod from Genesis

Genesis Energy has approved the construction of the Edgecumbe Solar Farm in the Bay of Plenty, marking its second major solar commitment in as many months.The company made a final investment decision (FID) on the 136 megawatt peak (MWp) farm, clearing the way for work to begin sh...